Group I (n = 113, 46.3%) | Group II (n = 14, 5.7%) | Group III (n = 38, 15.6%) | Group IV (n = 56, 23.0%) | Group V (n = 23, 9.4%) | Overall (n = 244, 100%) | |
---|---|---|---|---|---|---|
Gender (%) | ||||||
Male | 75.2 | 78.6 | 68.4 | 78.6 | 73.9 | 75.0 |
Female | 24.8 | 21.4 | 31.6 | 21.4 | 26.1 | 25.0 |
Age (years) | ||||||
Mean (standard deviation) | 54.8 (16.6) | 54.9 (22.9) | 55.5 (20.1) | 52.8 (18.7) | 51.3 (22.4) | 54.1 (18.5) |
Diagnosis of nosocomial pneumonia (%) | ||||||
Early onset | 8.0 | - | 7.9 | 14.3 | 13.0 | 9.4 |
Late onset | 92.0 | 100 | 92.1 | 85.7 | 87.0 | 90.6 |
Prior therapy (%) | ||||||
Antibiotics | 86.7 | 85.7 | 76.3 | 64.3 | 78.3 | 79.1 |
Steroids | 19.5 | 21.4 | 26.3 | 21.4 | 21.7 | 21.3 |
Vital signs (%) | ||||||
Fever (>38.2°C) | 50.4 | 42.9 | 71.1 | 55.4 | 39.1 | 53.3 |
Tachypnea (>20 cycles/minute) | 36.6 | 35.7 | 34.2 | 39.3 | 40.9 | 37.2 |
Systolic hypotension (<100 mmHg) | 37.2 | 57.1 | 47.4 | 33.9 | 43.5 | 39.8 |
Tachycardia (>110 beats/minute) | 30.4 | 35.7 | 23.7 | 28.6 | 30.4 | 29.2 |
Pulmonary function (%) | ||||||
PaO2/FiO2 < 250 mmHga | 85.2 | 81.8 | 89.3 | 83.0 | 50.0 | 81.5 |
Other therapies (%) | ||||||
Mechanical ventilationb | 76.1 | 85.7 | 92.1 | 87.3 | 95.5 | 83.5 |
Vasoactive drugs | 45.5 | 50.0 | 45.9 | 33.9 | 54.5 | 44.0 |
APACHE II score | ||||||
Mean (standard deviation) | 17.4 (7.0) | 17.6 (9.0) | 17.3 (8.3) | 16.0 (6.0) | 18.3 (7.8) | 17.2 (7.2) |
0–8 (%) | 8.0 | 14.3 | 15.8 | 8.9 | 4.3 | 9.4 |
9–16 (%) | 42.5 | 28.6 | 31.6 | 42.9 | 34.8 | 39.3 |
17–24 (%) | 33.6 | 28.6 | 39.5 | 42.9 | 43.5 | 37.3 |
>24 (%) | 15.9 | 28.6 | 13.2 | 5.4 | 17.4 | 13.9 |
Concomitant diseases (%) | ||||||
Any | 67.3 | 64.3 | 47.4 | 58.9 | 60.9 | 61.5 |
Cardiovascular disease | 25.7 | 42.9 | 21.1 | 21.4 | 30.4 | 25.4 |
Chronic respiratory disease | 25.7 | 21.4 | 10.5 | 17.9 | 21.7 | 20.9 |
Liver disease | 8.0 | 7.1 | 5.3 | 7.1 | - | 6.6 |
Renal dysfunction | 5.3 | 7.1 | 2.6 | 3.6 | - | 4.1 |
Active neoplasia | 4.4 | 14.3 | 2.6 | 8.9 | 17.4 | 7.0 |